Novasep Expands and Opens Subsidiary in India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Novasep Expands and Opens Subsidiary in India

Novasep, a provider of separation sciences services and fine chemicals, is expanding its presence in India with the opening of Novasep Process Engineering Services, a part of its industrial business unit. The new office will enable Novasep to further serve industries in India producing functional and commodity food and feed ingredients, milk derivatives, and bio-based chemicals. Novasep will continue to sell biopharma chromatography equipment and associated processes in India.

Novasep India will continue to collaborate with the Nilsan Nishotech Systems, which has represented Novasep in India for more than 20 years. Nilsan Nishotech will remain the exclusive agent for Novasep for industrial biotech and biopharma purification processes and systems in India.

Source: Novasep


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here